Voluntary Recall Information
Philips Respironics Sleep and Respiratory Care devices
Information for patients
Patient safety is our top priority. We are committed to completing the remediation for all affected patients to make sure you receive safe and effective therapy. We know that each situation is unique depending on your affected device and personal situation. If you have questions about the remediation process or need any additional support once you have received your replacement device, please visit our updated Contact and Support page. We have devices available to ship, and we are actively encouraging patients who have registered their device to visit the Patient Portal in case further action is needed before we can ship your replacement device / complete your remediation pathway.
I registered my affected device but have not yet received my replacement device or financial payment
If you registered an affected device and are still waiting for your replacement, it is likely because we need important information or consent from you. Without this information, we are unable to ship your replacement device. Depending on your affected registered device, you may have alternative options.
Ozone and UV light cleaning products are not currently approved cleaning methods for sleep apnea devices or masks and should not be used.
Latest updates
Philips response to recent media articles related to Philips Respironics’ voluntary recall notification/field safety notice
July 2023 latest results and conclusions for sleep therapy devices related to the impact of ozone cleaning shows no appreciable harm to health in patients
Philips Respironics completed the analyses for System One and DreamStation Go sleep therapy devices indicating that the volatile organic compounds (VOCs) and the particulate matter (PM) emissions related to foam degradation are within the appliable safety limits. Additional visual assessments have been performed and confirm the low prevalence of significant foam degradation.
Resolution of US economic loss litigation reached
Philips has reached an agreement, subject to Court approval, to resolve all economic loss claims brought by private plaintiffs in the United States related to the Philips Respironics voluntary recall of certain sleep and respiratory care devices.
Patients, hospitals and sleep labs eligible for benefits under the agreement do not need to take any action at this time in order to participate in the proposed settlement. The settlement must be approved by the Court, and additional information will be provided to you in the future.
All related inquiries should be directed to the third-party Settlement Administrator, Angeion Group. For more information, please visit www.RespironicsCPAP-ELSettlement.com or call 855-912-3432.
